HealthTurku - Introductions
|
| Kalervo Väänänen, Rector, Turku UniversityInnovation and research in Turku related to bio- and medical sciences Characteristics for the Turku region is scientifically cutting-edge, multidisciplinary expertise concerning medicine, biotechnology, and health technology. University of Turku, together with its strategic partners, thus offers not only high-quality education, but also a basis for innovations and novel business applications within the biomedical field. In particular, the Health Campus Turku is a significant multidisciplinary platform and knowledge cluster within medicine, social and health care and technology, offering unique opportunities for research-based business and novel collaborations between public and private sectors. |
| Carl Johan Sundberg, Head of Unit for Bioentrepreneurship, Karolinska InstitutetInnovation, entrepreneurship and management at Karolinska Institutet related to the life science industry and health care Karolinska Institutet (KI) with its 600 research groups focused on life science and health has since over 20 years been committed to putting research results to use through commercialization and industry collaborations. For that purpose, KI has established a holding company, a technology transfer company, an innovation office and an academic unit conducting education and entrepreneurship research and education. |
| Marketta Häkkänen, Bayer NordicHealing and feeding through partnership Turku plays a big role at Bayer. Mirena - the 1st Finnish Blockbuster in pharmaceuticals - is invented, developed and produced in Turku. Our expertise is polymer-based drug delivery technology. Finland is a great place for investments thanks to our innovation ecosystem and agility for collaboration. |
| Juhani Knuuti, Director, Turku PET Centre, University of TurkuHealthy Lifespan Healty Lifespan is a personalized approach on prevention, diagnostics and therapies for cardiovascular and metabolic diseases from newborn to old age. It aims to generate scientific discoveries leading to new individualized therapies and drugs, diagnostic methods, imaging applications and technologies as well as research based education and preventive actions for major diseases in the society. The science involves strong combination of basic, translational, clinical and population level research in cardiovascular and metabolic disorders. The focus is also on the specific impacts that includes scientific, medical, economical and societal effects. It aims to make significant contributions in provision of valuable information and knowledge for improved decision-making on the path towards better global health and well-being of people. The consortium includes multidisciplinary experts at Turku and Kuopio campuses. |
| Anna Godenhjelm, Wallac OyAnna Godenhjelm is the Managing Director of Wallac Oy, an Åbo based, fully owned subsidiary of PerkinElmer Inc, headquartered in Waltham, Massachusetts, USA. It was in Åbo where the foundations were laid for PerkinElmer’s international success in newborn screening and current recognition as the global leader with the largest market share, widest product range and over 560 million babies screened in more than 100 countries; all with products developed and manufactured in Åbo. |
| Other speakers and introductions: |